Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SolasCure logo — Transforming chronic wound care with a breakthrough wound th...

SolasCure

Transforming chronic wound care with a breakthrough wound therapeutic

Founded 2017 United Kingdom Cambridge, United Kingdom 17 employees Grant Total: $26.31M Biopharma, Biotechnology +1

General Information

Company Name SolasCure
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom
Employees 17
Industries Biopharma, Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with SolasCure. To contact SolasCure, visit solascure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SolasCure compare?

A PDF of SolasCure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SolasCure soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SolasCure

SolasCure is a UK-based startup dedicated to revolutionizing chronic wound care with its breakthrough enzymatic technology. The company's flagship product, Aurase Wound Gel, is designed to address the unmet needs in chronic wound care, catering to both hospitals, clinics, and homes. This product, comprised of tarumase, a highly-specific fibrinolytic enzyme isolated & cloned from maggot saliva in a hydrogel, aims to provide an easy-to-use, effective solution for wound debridement and preparation. Aurase Wound Gel has successfully completed Phase IIa trials, demonstrating its safety, effectiveness, and pain-free application. The company has received notable recognition and grants, such as the Biomedical Catalyst Grant from Innovate UK, the EIC Accelerator Grant from the European Innovation Council, and the Life Sciences Innovator award from the UK Department for Trade and Business. Furthermore, SolasCure is the winner of the 2019 URGO Mentorship Programme. Founded in 2017 as a spin-off from BRAIN Biotech AG, SolasCure has shown significant promise in the biopharma, biotechnology, and healthcare industries. With its headquarters in Cambridge, UK, the company is poised to make a significant impact in the field of chronic wound care. For more information, visit their website at www.solascure.com.

Business keywords: biologics company, wound care, chronic wounds, biomimicry, evidence-based medicine, investigational product, debridement technology, healthcare professionals, outpatient care, home care, biotech company, bio-based solutions, innovation, biological diversity, enzyme technology

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant £405.00K 1
Innovate UK
Innovate UK
20 Mar 2024
Series B £10.90M 5
Seneca Partners
Seneca Partners, BRAIN Biotech AG +3
27 Mar 2023
Series A £15.00M 4
Development Bank of Wales Seneca Partners
Development Bank of Wales, Seneca Partners +2
09 Aug 2021
Grant Undisclosed -
17 May 2021
Seed Round Undisclosed -
20 Aug 2018

SolasCure Alternatives & Competitors

View All Alternatives
SolasCure vs
Adamas Biotech Srl
Adamas Biotech Srl Italy

Advancing the state-of-the-art in nature-based healthcare solutions

Debt Financing
2-10 employees
Biotechnology, Health Care
SolasCure vs
Micreos
Micreos Switzerland

Micreos is a biotech company focused on discovering and developing recombinant technology

Venture round
21 employees
Biotechnology, Design
SolasCure vs
Comanche Biopharma
Comanche Biopharma United States

Our purpose is to make every pregnancy around the world safer.

Series B
29 employees
Biopharma, Biotechnology
View all alternatives

FAQ About SolasCure

Transforming chronic wound care with a breakthrough wound therapeutic
SolasCure was founded in 2017.
SolasCure is headquartered in Cambridge, United Kingdom.
SolasCure operates in Biopharma, Biotechnology and Health Care. Its work centres on biologics company, wound care, chronic wounds and biomimicry.
SolasCure has approximately 17 employees.
SolasCure has completed 5 funding rounds, raising a total of $26.31M. The latest funding stage is Grant.
Top alternatives and competitors to SolasCure include Adamas Biotech Srl, Micreos , Comanche Biopharma, Regenesis, RedDress Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SolasCure and Adamas Biotech Srl are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SolasCure, https://bouncewatch.com/company/solascure, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes